Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRT 543 (Primary)
Indications Acute myeloid leukaemia; Adenoid cystic carcinoma; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors Prelude Therapeutics

Most Recent Events

05 Dec 2024 According to a Florida Cancer Specialists & Research Institute media release, data from this study will be presented at the ASH Annual Meeting.
23 Nov 2022 Status changed from active, no longer recruiting to completed.
31 Aug 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com